MacroGenics-Logo-(transparent-background).png
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
December 18, 2020 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Aleafia Health - Science Seeding Wellness
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24, 2020 07:15 ET | Aleafia Health Inc.
SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder Aleafia Health medical clinics along with select physicians and...
Minerva logo
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
July 01, 2020 08:00 ET | Minerva Neurosciences, Inc
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexantCorporate...
20170406 Telix Logo.png
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
August 07, 2019 20:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Minerva logo
Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
June 24, 2019 07:30 ET | Minerva Neurosciences, Inc
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexantKey secondary endpoint,...
Minerva logo
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
May 13, 2019 08:15 ET | Minerva Neurosciences, Inc
Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar...
Minerva logo
Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates
March 12, 2018 07:30 ET | Minerva Neurosciences, Inc
Four late-stage trials underway, targeting schizophrenia, major depressive disorder and insomnia disorder Planning for commercialization moves forward  Management to host conference call today at...
Minerva logo
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder
September 05, 2017 08:00 ET | Minerva Neurosciences, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
August 03, 2017 07:30 ET | Minerva Neurosciences, Inc.
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half...
Minerva logo
Minerva Announces Amended Agreement for MIN-202 in Insomnia
May 31, 2017 16:05 ET | Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...